PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
5P maybe
You’ll be gone by 0.5p
Just the start
With $1.37 trillion of firepower available for the industry's top 25 companies, expect M&A activity to heat up in 2024 after a surge in activity at the end of last year. EY
https://www.fiercepharma.com/pharma/pharma-firepower-late-ma-surge-23-bode-well-prospects-24-report
Getting interesting
More very relevant emerging research on the importance of inflammasomes in treating respiratory diseases. In particular the role of NLRP3 which NFX research specifically targets.
Published 5th Jan 2024.
'The role of inflammasomes in human diseases and their potential as therapeutic targets'
Respiratory disorders
Inflammasomes are implicated in the pathogenesis of several respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary infection, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). As a result, inflammasomes have become a significant focus for research aimed at developing new diagnostic biomarkers and therapeutic avenues in pulmonary diseases and other respiratory disorders.
Asthma is a chronic inflammatory disease of the airways that affects inflammatory cells and cytokines in the lungs.238 Exposure to industrial products, microbes, or other allergens induces reversible limitations in airflow into and out of the lungs, as well as airway hyper-responsiveness. Persistent airway inflammation causes structural changes in airway tissues, known as airway remodeling, resulting in nonreversible airway obstruction and progressive loss of lung function. There is increasing evidence that NLRP3 inflammasome plays a role in asthma.
The end result of inflammatory pulmonary diseases is fibrosis. The NLRP3 inflammasome mediates pulmonary fibrosis through the IL-1β-IL-1Rs-MyD88-NF-κB signaling pathway.263 Moreover, studies also found that NLRP3 inflammasome could transform lung endothelial cells into epithelial-mesenchymal transition, promoting pulmonary fibrosis. Caspase-1 and IL-1β play vital roles in pulmonary fibrogenesis. Caspases-1enzyme cleavages the pro-IL-1β and allows secretion of IL-1β.264 Elevated IL-1β has a profibrotic effect, and usually occurs in combination with higher expression of IL-1Rs in fibrogenesis.265 A study on mouse primary lung fibroblasts showed that the NLRP3 inflammasome increases IL-1β production, leading to lung fibrosis when induced by bleomycin.266 Collectively, these investigations have helped to clarify the role of inflammasomes in the development of pulmonary fibrosis and may lead to the discovery of new treatment targets for various respiratory disorders.
https://www.nature.com/articles/s41392-023-01687-y
Really surprised there aren't more slaves around atm speaking carp
0.407p online quotes to buy on HL.
Moving time 1p+ coming fast for starters
🥱
This weeks rise is most welcome and a good start to the year. The lack of sells into strength are also a welcome relief.
It’s clear that the results are somewhat linked to this on a number of fronts.
Firstly, they confirmed the company is a going concern, this is something that certain posters have been saying for the past year would never be achieved. What’s more is that this was signed off by the auditors, again something certain posters said would never happen.
The removal of this doubt is key for some to invest.
Second, the company cash position was made clear. Yes, it’s not huge but again some posters were sowing the seeds of doubt saying there would be a placing back in July and then in December, none of which materialised.
Thirdly. The results explicitly state that nxp004 is under discussion with potential partners, this is the first time this has been seen in writing.
They have also indicated that they are open to co-development of products with third parties to extend patent protection for products. Whilst not a priority this could be a revenue generating business model that supplements the company whilst moving NFX assets forward with a partner.
There’s lots to pick up on from the results which are the primary source of the rally from this week.
You need help, Ffx!
"The price in rising in anticipation of Dan Golding and team bringing home a stonking deal,that could blow us out of the water"
Is that the same deal we've been waiting for since 2019 when we were 14/15p per share?
Peverill, share price rises are all very nice unless they're based on BS in which case we'll all be back to square one next week or the week after.
Let's see what happens. I've been proved wrong about the bid today. Would love to be proved wrong again.
Whimax, sit! 🐶
"Awww bless… you believe the monetary value of trades determines Mcap. Lol!"
No. You said you do:
"Because there were more buys than sells."
Can’t believe you just posted that Ffx!! 😂🤡
“ £22k in transactions = £320k rise in capital ”
Awww bless… you believe the monetary value of trades determines Mcap. Lol!
Gooding,f’ing autocorrect.
The price in rising in anticipation of Dan Golding and team bringing home a stonking deal,that could blow us out of the water,from where it has been in the doldrums over the last few years.Given the crap we have endured over the last few years,we are lucky the company is still standing,hopefully the phoenix is about to rise from the ashes.GLA
£22k in transactions = £320k rise in capital
I like your reasoning. You should be on the board!
Because there were more buys than sells.
Not at all. It's nice....but why?
Are you unhappy that the sp has gone up?
Are you happy that it's all on thin air though?
Happy enough with this first week of the year.
Good job we were never anchored to 0.3
Aw! Lovely! ☺️